+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sutent"

Kidney Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Kidney Cancer Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Renal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Renal Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
Global Proto Oncogene Market & Clinical Pipeline Insight 2024 - Product Thumbnail Image

Global Proto Oncogene Market & Clinical Pipeline Insight 2024

  • Drug Pipelines
  • February 2018
  • 440 Pages
  • Global
From
From
From
From
Avastin (bevacizumab; Genentech/Roche/Chugai) Drug Overview 2019 - Product Thumbnail Image

Avastin (bevacizumab; Genentech/Roche/Chugai) Drug Overview 2019

  • Drug Pipelines
  • March 2019
  • 111 Pages
  • Global
Inlyta (axitinib; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Inlyta (axitinib; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 20 Pages
  • Global
Torisel (temsirolimus; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Torisel (temsirolimus; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 24 Pages
  • Global
Sutent (sunitinib; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Sutent (sunitinib; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 19 Pages
  • Global
Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview 2019 - Product Thumbnail Image

Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview 2019

  • Report
  • September 2019
  • 29 Pages
  • Global
Renal Cell Cancer Pricing, Reimbursement, and Access - Product Thumbnail Image

Renal Cell Cancer Pricing, Reimbursement, and Access

  • Report
  • August 2018
  • 91 Pages
  • Global
From
Tyrosine Protein Kinase ITK/TSK - Pipeline Review, H1 2020 - Product Thumbnail Image

Tyrosine Protein Kinase ITK/TSK - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 66 Pages
  • Global
From
Sutent - API Insight, 2022 - Product Thumbnail Image

Sutent - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Sutent- Drug Insight, 2019 - Product Thumbnail Image

Sutent- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
Afinitor (everolimus; Novartis) Drug Overview 2019 - Product Thumbnail Image

Afinitor (everolimus; Novartis) Drug Overview 2019

  • Report
  • March 2019
  • 30 Pages
  • Global
  • 19 Results (Page 1 of 1)
Loading Indicator

Sutent (sunitinib) is an oncology drug used to treat certain types of cancer, including gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (PNET). It is a small molecule tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Sutent is typically administered orally, and is available in both capsule and tablet form. Sutent is a widely used drug in the oncology market, and is often prescribed as a first-line treatment for certain types of cancer. It is also used in combination with other drugs to treat more advanced forms of cancer. The Sutent market is highly competitive, with many companies offering similar products. Some of the major players in the market include Pfizer, Novartis, Merck, and AstraZeneca. Show Less Read more